Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Receivables (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Receivables for 12 consecutive years, with $261000.0 as the latest value for Q1 2026.

  • For Q1 2026, Receivables fell 85.21% year-over-year to $261000.0; the TTM value through Mar 2026 reached $261000.0, down 85.21%, while the annual FY2025 figure was $1.1 million, 27.87% up from the prior year.
  • Receivables hit $261000.0 in Q1 2026 for Cartesian Therapeutics, down from $1.1 million in the prior quarter.
  • Across five years, Receivables topped out at $35.5 million in Q2 2024 and bottomed at $261000.0 in Q1 2026.
  • Average Receivables over 5 years is $7.6 million, with a median of $6.4 million recorded in 2023.
  • Year-over-year, Receivables surged 451.41% in 2024 and then plummeted 99.0% in 2025.
  • Cartesian Therapeutics' Receivables stood at $9.8 million in 2022, then dropped by 9.29% to $8.9 million in 2023, then tumbled by 90.15% to $872000.0 in 2024, then grew by 27.87% to $1.1 million in 2025, then plummeted by 76.59% to $261000.0 in 2026.
  • According to Business Quant data, Receivables over the past three periods came in at $261000.0, $1.1 million, and $722000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.